<DOC>
	<DOCNO>NCT02309892</DOCNO>
	<brief_summary>The primary purpose research study evaluate safe , well tolerate effective range dose L-DOS47 combination standard doublet therapy pemetrexed/carboplatin patient Stage IV ( TNM M1a M1b ) recurrent metastatic non-squamous Non-Small Cell Lung Cancer .</brief_summary>
	<brief_title>A Dose Escalation Study L-DOS47 Recurrent Metastatic Non-Squamous NSCLC</brief_title>
	<detailed_description>It plan patient receive 4 cycle combination treatment L-DOS47 + pemetrexed/carboplatin . Patients progress follow 4 cycle combination treatment experience unacceptable toxicity opportunity continue receive L-DOS47 treatment long clinical benefit well-tolerated , opinion Investigator , disease progression . Patients unable complete 4 cycle L-DOS47 + pemetrexed/carboplatin combination treatment due pemetrexed/carboplatin toxicity opportunity continue receive L-DOS47 treatment follow discontinuation pemetrexed/carboplatin , long clinical benefit well-tolerated , opinion Investigator , disease progression .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Immunoconjugates</mesh_term>
	<criteria>Main 1 . Male female patient ≥ 18 year age 2 . Histologically cytologically confirm nonsquamous NSCLC 3 . EGFRmutation positive patient must progress intolerance EGFR small molecule tyrosine kinase inhibitor 4 . Patients whose tumor harbor anaplastic lymphoma kinase ( ALK ) translocation must progress intolerance ALK inhibitor ; 5 . No prior adjuvant chemotherapy within 1 year first treatment day recurrent disease 6 . At least 1 site measurable disease per Response Evaluation Criteria Solid Tumors ( RECIST ) v1.1 7 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 minimum life expectancy ≥ 3 month 8 . Adequate bone marrow , renal liver function Main 1 . Histologic evidence predominantly squamous cell NSCLC 2 . Brain metastasis and/or leptomeningeal disease ( know suspect ) 3 . Peripheral neuropathy &gt; CTCAE grade 1 4 . Possibility curative local treatment ( surgery and/or radiotherapy ) 5 . Previous chemotherapy except adjuvant treatment progression disease document ≥ 12 month end adjuvant treatment 6 . Having receive treatment another clinical study within 30 day prior commence study treatment side effect prior study drug recover grade ≤ 1 baseline , except alopecia 7 . Concurrent chronic systemic immunotherapy , chemotherapy hormone therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Non-Small Cell Lung Cancer</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Immunoconjugate</keyword>
	<keyword>Tumor microenvironment alkalinization</keyword>
</DOC>